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Abstract
Background: The popularity of complementary and alternative medicine (CAM) has led to a
growing amount of research in this area. All the same little is known about the effects of these
special treatments in every-day practice of primary care, delivered by general practitioners within
the health insurance system. From 1994 to 2000 more than 20 German Company health insurances
initiated the first model project on CAM according to the German social law. Aim of this
contribution is to investigate the effectiveness of multi-modal CAM on chronic diseases within
primary health care.
Methods:  A long-term prospective intermittent study was conducted including 44 CAM
practitioners and 1221 self-selected chronically ill patients (64% women) of whom 441 were
employed. Main outcome measure is sick-leave, controlled for secular trends and regression-to-
the mean and self-perceived health status.
Results: Sick-leave per year of 441 patients at work increased from 22 (SD ± 45.2) to 31 (± 61.0)
days within three years prior to intervention, and decreased to 24 (± 55.6) in the second year of
treatment, sustaining at this level in the following two years. Detailed statistical analysis show that
this development exceeds secular trends and the regression-toward-the-mean effect. Sick-leave
reduction was corroborated by data on self-reported improvement of patients' health status.
Conclusion: Results of this longterm observational study show a reduction of sick leave in
chronically ill patients after a complex multimodal CAM intervention. However, as this is an
uncontrolled observational study efficacy of any specific CAM treatment can not be proven. The
results might indicate an general effectiveness of CAM in primary care, worthwhile further
investigations. Future studies should identify the most suitable patients for CAM practices, the most
appropriate and safe treatments, provide information on the magnitude of the effects to facilitate
subsequent definitive randomised controlled studies that will help to position complementary and
alternative medicine in health care.
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Background
The dilemma is becoming ever more obvious: although
mainstream medicine, science and health policy refuse
Complementary and Alternative Medicine (CAM) as
being scientific and efficient, the popularity of the use of
CAM is at a premium and growing [1-5]. This conflicting
situation is, above all, fostered by the still prevailing short-
comings of good scientific evidence for efficacy and effec-
tiveness of CAM procedures, as well as by the increasing
chronic diseases within the population – those disease
patterns for which mainstream medicine itself acknowl-
edges having no satisfactory solutions.
Against this background, 22 German company health
insurance funds (BKK) in the Rhine-Ruhr area initiated a
project according to the German social law lasting from
1994 to 2000. Only within this project, health insurances
were allowed to pay for CAM therapies.
The scientific evaluation of the project had to be carried
out on account of legal requirements. Therefore, an obser-
vational study with quality control steps according to
standard operation procedures (SOP) has been per-
formed, committing sickness absence as a main study out-
come. Sickness absence is widely accepted as an
objectively and integrated measure of morbidity in the
working population [6-10], though it is still a seldom
used outcome measure in epidemiological/clinical stud-
ies. Even more seldom are studies which directly link
absenteeism as one outcome variable and the individual
health status [11].
The purpose of the study is to provide profound informa-
tion about the effectiveness of CAM in chronically ill
patients. The purpose, however, is not to prove that a spe-
cific CAM treatment is effective for a specific disease.
Rather, it is meant to investigate possible longterm effects
in everyday practice in primary care. In this contribution,
we examine the overall effectiveness of CAM interventions
on trends in sick-leave, together with patients' health
related quality of life. Particularly, we investigate the
extent of the regression-towards-the-mean effect, an often
ignored ubiquitous statistical phenomenon in pre-/post-
treatment measurements [12-14].
Methods
We conducted a longterm prospective cohort study with
intraindividual pre/post comparisons using patients'
questionnaires, documentations of the participating phy-
sicians, and health insurance data.
Study participants were self-selected patients recruited by
the involved health insurance funds, the participating
physicians and press articles during 1994 – 2000. All indi-
viduals gave written informed consent. Due to the assess-
ment of real-life practice in primary care the only
inclusion criteria were the membership to one of the par-
ticipating health insurance funds and the presence of a
non-life-threatening chronic disease (e.g. back pain,
migraine, skin diseases, allergies) that has not been
improved with conventional therapies, or for which,
according to medical experience, a cure or relevant
improvement could not be expected. All participating
CAM practitioners had to be medical doctors and quali-
fied for the CAM treatments they provided. A wide range
of CAM procedures for reimbursement have been author-
ised by the federal insurance office especially for this
project (table 1).
Data was collected from different sources: Case report
forms for documenting therapy processes and data of rou-
tine health insurance records (sickness absence, in hospi-
tal, medication). Patients' self-administered
questionnaires comprising health status, on the basis of
the questionnaire of the German National Health Survey
(NHS). The NHS was part of the German Cardiovascular
Table 1: Specifically approved Complementary and Alternative Medicine Procedures*
Diagnostic Procedures Therapeutic Procedures
holistic anamnese (up to 1 hour) acupuncture
decoder electric acupuncture (except: according to Voll)
„Lüscher" test neuraltherapy
regulation thermography homoeopathy
electric acupuncture (not by Voll) colon therapy
oxygen therapies except: oxyon-, hyperbaric oxygen- and oxygen 
multistep-therapy
manual therapy
reflexzone therapy
orthomolecular medicine
isotherapy
symbiosis regulation
* Especially for this project approved procedures, most of them outside of the regular health insurance reimbursement system. Further procedures 
like phytotherapy, face time were regular procedures regarding reimbursement at that timenot needing special approval.BMC Public Health 2006, 6:28 http://www.biomedcentral.com/1471-2458/6/28
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Prevention Study [15], that comprises three nationwide
cross sectional surveys in the former West Germany
between 1981–1996. The NHS is a major source of the
German health reporting system and is provided as public
use files, frequently used for scientific research.
Sick-leave days (SLD) and duration of sickness leave per
case (DSL) served as indicators for morbidity. The cumu-
lative sick-leave incidence (CSLI, the proportion of
patients with any sick-leave in a given observation year)
served as ill health indicator for the whole study group.
Standardised rate ratios (SRR) for SLD were obtained by
dividing sick leave days by the mean values in strata
defined by age classes and gender in the reference popula-
tion. As reference population all members of the German
Company Health Insurance Funds were chosen. Sick leave
data of the reference population are documented in the
annual health reports [16].
Patients outcome assessments were done at baseline
before start of treatment, at the end of treatment, and at
follow up 1.5 years after the end of treatment (figure 1).
Health data collection occurred retrospectively up to 5
years, depending on the availability of health records at
the health insurance funds for each patient. Time span of
prospective data collection depended on duration of ther-
apy (maximum 5 years) and availability of health records
in the follow up period (max. 5 years). For purposes of
analysis we chose the time span -3 to +4 years, since the
years -4 and -5 seemed not to be informative for possible
treatment effects. Nevertheless data of the years -4 and -5
were used to calculate regression to the mean effects. For
one subgroup analysis we used a narrower range of -2 to
+4. Furthermore data of the fifth year of follow up are not
presented here, since the number of patients with availa-
ble data was very small (n = 35) at the time of analysis.
Statistical analysis
The SLD distribution shows strong positive skewness with
40% of the patients having no sick-leave in a given obser-
vation year. Applying a log-transformation reveals an
excess of patients with no sick leave in a given observation
year. Therefore, we treat the number of patients without
sick leave – or its complement, the CSLI per year – as a dis-
tinct parameter for sick-leave in the entire study group.
The CSLI and measures of SLD and SRR distributions
characterise the time dependence of sick leave in the study
population. The quartiles of those measures are presented
with their 95% confidence intervals (95% CI).
Changes in the CSLI are subjected to a χ2-test-of-fit to a
uniform distribution over the observation years. Repeated
measures multivariate analysis of variance based on ranks
was used to explore changes in SLD. The repeated meas-
ures design confines analysis to dependent samples, that
is, to well defined subcohorts with non-missing sick-leave
data in every observation year compared.
The kind of study design – observational long term study
including retrospective data, a pre/post comparison, no
explicit control group and highly selected patients – sug-
gests an effect of regression-toward-the-mean (RTM) in
our data [12,17,18], a statistical phenomenon, first
defined by Galton [12]. RTM originates from selection by
value and poor correlation of variables, and is of particu-
lar importance for repeated measurements as in longitudi-
nal studies. In short: RTM is associated with Pearsons'
correlation r between e.g. the measured values of a quan-
tity at one point in time and the values of the same quan-
tity at the next point in time. The effect, observable in
subgroups selected by the value of the quantity (for exam-
ple, the upper 25% of the population at the first point in
time) is strongest for zero correlation and vanishes at r =
1. Unawareness of this phenomenon may lead to misin-
terpretation of data.
In order to check up on RTM we (1) controlled for com-
mon societal trends standardising sick-leave data to the
population of all German company health insurances
(SRR). Assuming that sick-leave five to four years before
inclusion to the study is independent from study partici-
pation, we (2) estimated the effect of RTM from the fifth
to the fourth year in our cohort: the strongly skewed dis-
tributed SRR is represented by the classes (SRR = 0,
0<SRR< = 1, SRR>1), correlation is then given by a transi-
tion matrix between adjacent points in time (years). We
observed that in both remote years five and four years
before inclusion, mean SRR in the model experiment was
stationary at 0.86 for 321 patients with sick-leave data
reported in both these years. The respective 95%CIs are
0.69–1.03 five years and 0.7–1.02 four years before inclu-
sion, indicating comparable sick leave levels of the
Pattern of data collection Figure 1
Pattern of data collection.
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patients to the level in the reference population five and
four years before enrolment. A mean SRR slightly lower
unity may be accountable for by demographic characteris-
tics of patients volunteering for CAM treatment. (3) For
the present argument, the observed steady state of mean
SRR is decisive. We therefore may estimate the matrix
describing the process of regression-toward-the-mean in
the reference population from the participants' data in the
indicated consecutive remote years. Multiplying this esti-
mate for the transition matrix with the vector of class per-
centages in a given year yields the class percentages in the
next year as expected under regression-toward-the-mean.
To compare classified SRR distributions between years we
employed Cochran-Mantel-Haenszel (CMH) statistics.
Note, that all significance levels associated with the above
tests are understood to be strictly descriptive. Analyses
were performed with SAS software package.
Results
Fourtyfour practitioners treated 1221 patients, 441 of
whom were employed and might take sick leave. Baseline
characteristics are described in table 2. The following
results are on the basis of the working cohort. As main
diagnosis dorsopathies (23.7%), osteoathrosis/-athritis
(9.1%), skin diseases (8.0%), headache/migraine (6.9%),
and chronic obstructive lung diseases (5.5%) were docu-
mented most often. With the exception of cardiovascular
diseases, a similar distribution of diseases can be found in
the reference population [17]. Before treatment, the mean
duration of disease was 10.6 years, and on average six dif-
ferent conventional therapies with respect to the main
diagnosis were recorded.
Standardising our data according to age and sex, study
participants represent a higher social status than the NHS
population. The greatest differences appeared, as
expected, in reference to the health status: patients
engaged more in sports, cared more for their health and
were to a higher degree convinced that one can influence
ones own health status. The current health state was con-
sidered to be much poorer, and distress such as backache,
pain in neck and shoulders, feeling of weakness, and wea-
Table 3: Sick leave days per patient and year, stratified by sex (unstandardized)
Year Sick leave days/patient/year
All Women Men
N* Mean (SD) Median 
(95%CI)
n Mean (SD) Median 
(95%CI)
n Mean (SD) Median 
(95%CI)
-3 369 22 (45.2) 5 (4; 9) 193 19 (40.7) 6 (4; 9) 176 24 (49.8) 5 (3; 10)
-2 404 25 (47.5) 7 (4; 9) 216 22 (33.0) 8 (5; 12) 188 29 (59.9) 4 (1; 9)
-1 441 31 (61.0) 9 (6; 12) 242 29 (58.2) 8 (5; 12) 199 33 (64.2) 10 (6; 14)
1 441 28 (57.5) 9 (7; 11) 242 26 (56.8) 8 (5; 11) 199 30 (58.4) 11 (7; 16)
2 397 24 (55.6) 5 (3; 7) 218 24 (51.3) 5 (3; 8) 179 25 (60.5) 5 (0; 8)
3 297 21 (47.0) 5 (2; 7) 159 18 (34.9) 5 (1; 8) 138 25 (57.8) 5 (0; 10)
4 196 20 (46.1) 4 (0; 6) 102 21 (12.9) 5 (0; 9) 94 20 (50.5) 1 (0; 5)
*Note: Since participants entered the study at different points of time, the follow up period could not be equal for all patients, which causes a drop 
of observed participants especially in the third and fourth year.
Table 2: Baseline characteristics of the study population
Whole study population (n = 1221) Study population at work (n = 441)
Women (%) 63.9 54.9
Age (years), mean (± SD) 42.5 (17.4) 41.8 (10.5)
Duration of disease (years), mean (± SD) 10.1 (9.7) 10.6 (9.9)
Duration of treatment (years), mean (± SD) 1.9 (1.2) 2.0 (1.2)
Health status*, mean (± SD)
Before treatment 3.2 (0.86) (response: 93.9 %) 3.2 (0.82) (response: 97.5 %)
After treatment 2.7 (0.91) (response: 74.3 %) 2.6 (0.91) (response: 74.6%)
Follow up** 2.6 (0.94) (response: 51.1 %) 2.6 (0.88) (response: 54.7%)
* score built from following items: frequency and duration of pain, state of health, degree of impairment, range from 1 – 5, from 1 = excellent to 5= 
poor health.
** 1.5 years after treatment.BMC Public Health 2006, 6:28 http://www.biomedcentral.com/1471-2458/6/28
Page 5 of 9
(page number not for citation purposes)
riness were more often represented among study partici-
pants compared to the German population.
The mean CAM treatment lasted 2.0 years (mean interven-
tion time). Patients were treated on average with three dif-
ferent therapy modalities, with acupuncture, face time,
homoeopathy, oxygen therapy, and neuraltherapy as the
most often used. Surprisingly, phytotherapy seemed to
have only a small meaning, although of the drug groups
practitioners prescribed most often, phytotherapeutics
ranked on the fourth place with 7%, besides homoeo-
pathics (15%), vitamins/minerals (9%) and bacteria
lysates (8%).
Average loss of sick-leave days amounted to 31 (SD ±
61.0) days in our cohort prior to inclusion (table 3) and
exceeded absenteeism of the reference population [16].
The distribution of SLD showed a noticeable time
dependence in coincidence with CAM treatment. A deep
drop of SLD down to 24 days occurred mainly in the sec-
ond year after enrolment, remaining at this low level in
the following years (table 3). Since 80% of treatments
lasted less than three years this might indicate a sustaina-
ble effect of CAM interventions on sick-leave.
Classifying patients as those without any sick-leave, with
durations less than 1 week, 1–3 weeks and longer than 3
weeks in one given observed year, there was a marked shift
towards a higher proportion of patients with lower sick-
leave durations: 39% in the second year compared to 32%
before start of treatment for those with no sick leave and
18% in the second year compared to 15% before start of
treatment for those with durations less than 1 week (fig-
ure 2). This shift persisted in the following years. Further-
more, the proportion of patients with durations >6 weeks
in one given sick-leave case was sustainably lowered (fig-
ure 3), which is especially of high economical interest for
the health insurances, since by German social law they
have to take upon the salary of their members from the
43rd day on.
Table 4 shows the time course of the mean and 75. percen-
tiles (Q3) of the SRR in a subcohort of patients with
recorded data in all observation years. Taking into account
the 95%CIs, mean and Q3 were distinctly larger than the
reference value SRR = 1 until the first year of treatment.
Thereafter in the prospective period, Q3 is comparable to
unity, which means that 75% of the patients had the same
amount or less sick-leave than expected for their age and
gender in the reference population.
Stratifying sick-leave data by health improvement as a sur-
rogate indicator for good/poor success of CAM interven-
tion, table 5 shows the proportion of patients with
improved versus impaired or unchanged self-reported
health status. More than 70% reported an improvement.
With regard to sick-leave, figure 4 unmasks a quite reveal-
ing pattern of sick-leave development. Before CAM inter-
vention, the SLD distribution is similar in both groups;
but in the second year of intervention, the SLD of the
improved patients dropped clearly, contrary to non-
improved patients.
Up to this point, the observed development of sick-leave
could solely be the spurious effect of regression-toward-
the-mean (RTM). Figure 5 shows the observed distribu-
tions in SRR in the first year of treatment: 30.5% with no
sick leave compared to the population of all German com-
pany health insurances (SRR = 0), 35.3% with equal sick
leave day (SRR 0,1), and 34.2% with more sick leave
(SRR>1). Under regression-toward-the-mean we expect
30.7%, 37.0% and 33.3% in the second year. Nonethe-
less, the observed SRR-distribution in the study popula-
Proportion of patients with longterm sick leave (>six weeks  in one given case) Figure 3
Proportion of patients with longterm sick leave (>six weeks 
in one given case).
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tion in the second year is 39.6%, 36.9%, 23.5% (figure 5).
This suggests a relevant net decrease of standardised sick-
leave days.
Discussion
Characteristics of our study cohort are typical for user of
CAM: On average, they are more likely middle aged,
female, multimorbid, higher educated, of poorer subjec-
tive health, with chronic pain, non-life-threatening health
problems and are high utilisers of the health care system
[4,19-22]. The latter item is especially interesting since our
outcome parameter, absenteeism, is an internationally
established indicator for work related morbidity [6], and
was also used to study effects of acupuncture in ran-
domised trials [23]. Furthermore absenteeism imposes
considerable direct and indirect costs on the employer
and health insurances. Accordingly, the revealed sus-
tained reduction of absenteeism, exceeding regression-
toward-the-mean effects and societal trends, might indi-
cate at least an indirect economical effect of the multifac-
eted CAM intervention, particularly with regard to the
reduction of long spells. Together with the improvement
of the health status this is a plausible argument for a ben-
eficial treatment for this kind of patients. Up to which
degree the observed effects might have an overall econom-
ical benefit has yet to be proven.
The observed pattern of sick leave with higher rates of
absenteeism in men is different to results of many other
epidemiological studies reporting consistently higher lev-
els of absenteeism in women [e.g. [7,24-26]]. This could
be due to the patient-based cohort group here, with espe-
cially highly selected chronically ill men. Since it is known
that women prefer CAM therapies, one can assume, that
only those male study members entered the study, show-
ing the highest perceived morbidity. Self-perceived well-
being on the other hand is in some way associated with
taking sick leave [27].
In Germany, almost all insurance companies initiated
projects according to the German social law [28,29].
Although none of them included this wide spectrum of
CAM therapies – homoeopathy and acupuncture are
mostly involved – those examining sick-leave found sim-
ilar results [29]. Contrasting to our study, they did not
control for regression-toward-the-mean and secular trend.
However, the evaluation of these projects will give com-
prehensive insights into the use of CAM in primary care
patients. In the period from 1995–2007 the insurance
Table 5: Proportion of patients with improved versus unchanged or impaired selfreported health status after treatment
Health status after 
treatment
All Men Women
n%n%n%
improved 229 71.1 92 66.7 137 74.5
Unchanged/impaired 93 28.9 46 33.3 47 25.5
All 322 100 138 100 184 100
Score built from items '"frequency of pain" and "duration of pain", "state of health", degree of "impairment".
Table 4: Standardized Rate Ratio (SRR) of the sick leave quota*
Observation year1 Standardized Rate Ratio
Mean 95%CI2 Q33 95%CI2 P4
-2 1.19 0.82;1.57 1.33 0.95;1.78 0.26
-1 1.44 1.05;1.82 1.52 1.18;1.88 -
1 1.45 0.92;1.98 1.34 1.10;1.64 0.90
2 1.04 0.67;1.42 0.96 0.65;1.36 0.03
3 1.12 0.69;1.54 1.01 0.76;1.48 0.01
4 1.10 0.71;1.54 1.01 0.75;1.52 0.02
* Subcohort of patients at work with nonmissing data (n = 187), standardised to German company health insurance population, 
stratified by calendar year, sex and age.
1 time period with regard to the time of beginning of the treatment of the patient (-3 = observation year three years before, 1 = first observation 
year after treatment and so one);
2 95% confidence intervall;
3 75. Percentile, a SSR-Q3 of 1.0 means that in that given observation year 25% of the observed patients show the same sick leave durations as in 
their corresponding reference group regarding age and gender;
4 P-value contrasted to the observation year -1.BMC Public Health 2006, 6:28 http://www.biomedcentral.com/1471-2458/6/28
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funds in Germany will altogether have spent approxi-
mately € 510 million for CAM treatments and their scien-
tific evaluations (€ 12 mio) [30].
Within this project study physicians were allowed to prac-
tice a variety of CAM procedures without financial restric-
tion. On a first glance, this might be quite unfavourable
for evaluation purposes. Otherwise, for the first time, we
are able to achieve insights of general practices of CAM
practitioners in primary care.
Concerning study limitations (1) a major bias might
derive from a spontaneous regression of disease, but this
seems unlikely given the long-term chronic condition of
the patients and the very long observation time. (2) Study
subjects were not aware of the fact that the principal out-
come would be absenteeism, so it is unlikely to assume
that participants were less absent from work because of
their knowledge about the main outcome. (3) The
observed temporal course of sick-leave could rely only on
regression-toward-the-mean, especially with this highly
selected group of patients. But again, the long retrospec-
tive and prospective time span observed made it possible
to control for regression-toward-the-mean, demonstrating
an effect that exceeds this phenomenon. (4) A potential
bias might arise from different sample sizes at different
observations years. However, neither a last observation
carried forward nor a complete case analysis resulted in
major modifications of our results. (5) It must be taken
into account that the feature of being unfit to work is
influenced by several confounding factors [31,32]. A
remarkable influence on the number of SLDs is the sever-
ity of the chronic disease, as well as different kinds of
working conditions and workload. Absenteeism is a com-
plex process, and although a poor health status is related
to higher rates of absenteeism [33], there are also different
coping behaviours that influence taking sick-leave [34].
This phenomenon might explain the relatively high pro-
portion of chronically ill patients without any sick-leave
in one given year. Nevertheless, the pattern of our sick-
leave data, combined with self-reported health status is
consistent with constant effects of the CAM intervention
on sick-leave in our cohort. (6) At least, possible co-inter-
ventions might have influenced the observed changes.
During the observation period patients could have
received additional conventional treatments. When ask-
ing patients for further therapies, we found that more than
60% received additional treatments, but in most instances
these referred to treatments of dentists, gynaecologists,
ophthalmologists or orthopaedists, seldom to treatments
of radiologists, neurologists, ENTs. Less than 5% of the
patients reported co-intervention from other general prac-
titioners. So the impact of co-intervention seemed to be
low at a first glance. Nevertheless, when analysing the pre-
scription patterns of the study practitioners, we could find
some (modern) conventional pharmaceutical therapies,
e.g. Aarane, a bronchodilatator for asthma [35]. Further
analysis are planned to describe the diverse strategies of
CAM practitioners regarding treatment patterns, number
of different CAM specialities and conventional therapies
used, treatment durations, costs in association with
patients satisfaction and health improvement.
Finally, some comments on the relevance of our results
have to be made relating to the observational study
design. With the special situation of evaluating a project
according to the German social law, we had to regard
some conditions that differ from clinical studies. First,
Controlling for regression to the mean Figure 5
Controlling for regression to the mean. Development of pro-
portions of patients (subcohort, n = 187) with no (SRR = 0), 
equal (SRR 0,1) or more sick leave (SRR>1) in the first and 
second year after treatment compared to the reference pop-
ulation with observed and expected proportions (under the 
assumption of regression towards the mean). Test: 1. vs. 2. 
year p = 0.01 (CMH), expected vs. 2. year: p = 0.02 (CMH).
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establishing a reliable control group was not feasible since
patients interested in participating were highly in favour
of being treated with this variety of CAM interventions. It
is known from other studies that patients with a strong
preference for a particular treatment will refuse randomi-
sation [36,37]. What is more, it had to be expected that
our chronically ill patients would refuse those conven-
tional therapies which they had already experienced with-
out success years before. Second, logistical reasons
excluded a random invitation. Third, no comparable pop-
ulation with definitely no access to CAM was available
due to data protection reasons and lack of interest of con-
ventional practitioners to cooperate. The absence of a suit-
able control group could partly be compensated by the
long observation time and by the use of routine health
data for comparison, but nevertheless limits the generalis-
ability of our conclusions.
Profound observational studies are pragmatic approaches
to questions concerning the practices used for particular
diseases, the numbers and types of patients who use them,
and how well patients respond to treatment [38]. There-
fore, the evaluation of this intervention project reveals
comprehensive insights of multi-modal CAM use in gen-
eral practice. The value and meaning of results of well-
designed observational studies have been extensively dis-
cussed [39-45] and we agree with Rosenbaum [46], who
states that results from observation studies strengthen the
evidence, but do not prove the treatment caused its osten-
sible effects. We are well aware of the fact that this study
by no way could adress the question of efficacy (efficacy
here refers to an intervention that has been shown to be
superior to placebo in randomised controlled trials) of
any of the CAM treatments applied. It is meant to show
possible long-term effects in association with the special
intervention in real-life practice. The definition of a rele-
vant endpoint, the confirmation of a study protocol with
a clear study question and the provision for quality assess-
ment as prerequisites of a careful observational study [47],
make this study an approach in which an investigation of
a whole system has been undertaken in its proper context.
Conclusion
Extensive research in CAM is needed, that will help to
define the place of these interventions in health care. This
is called for, seeing as the continuing public demand for
CAM, combined with still missing sound scientific
research, will affect and challenge health care delivery.
From a public health perspective we definitely need to
answer questions such as: Which procedures of CAM are
safe and effective and for which group of patients? How
does CAM meets health care needs, and is CAM associated
with high usage of all type of health care? The answering
of these questions has to consider social, cultural, politi-
cal, and economic contexts to maximize the contribution
of CAM to the health care system globally. Therefore we
need the whole scope of scientific methods available –
experimental and randomized controlled trials to out-
come studies – in order to be able to make informed and
rational decisions within the health care system. What is
urgently needed to cope with these challenging tasks is a
comprehensive and targeted funding for CAM research,
which is almost completely missing in most countries.
Altogether this study provides another small building
block for the long-term objective of a pragmatic integra-
tion of mainstream medicine and CAM that better meets
the needs and wishes of all patients – not only in Ger-
many.
Abbreviations
CAM = complementary and alternative medicine, CI =
confidence interval, CSLI = cumulative sick-leave inci-
dence, DSL = duration of sickness leave per case, ENT = ear
nose and throat, NHS = German National Health Survey,
RTM = regression-toward-the-mean, SLD = sick-leave
days, SRR = standardised rate ratio
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SM carried out the study and contributed to the acquisi-
tion of data, interpretation of data, and drafted the manu-
script. NL performed the statistical analysis. WB has been
involved in the interpretation of data, and statistical anal-
ysis. KHJ conceived of the study, and participated in its
design and helped to draft the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
We sincerely thank the following individuals for their commitment and 
helpful work: Herbert Hirche for his scientific contribution, Claudia Ose 
and Anja Marr for their excellent research assistance, and Roswitha Beneda 
for her reliable longtime data management. We thank the personnel of all 
participating Company Health Insurances (BKKs) for their help in providing 
routine health records. We wish to thank the Zentrum zur Dokumentation 
für Naturheilverfahren, Essen, especially Dr. Schlebusch and Marianne Kol-
venbach for the coordination of the technical part of the study, and special 
thanks to the participating practitioners for their engagement. At last we 
are very grateful to Lorraine Frisina for her carefully proof-reading of the 
manuscript.
References
1. Fisher P, Ward A: Complementary Medicine in Europe.  BMJ
1994, 309:107-111.
2. MacLennan AH, Wilson DH, Tayloy AW: Prevalence and cost of
use of alternative medicine in Australia.  Lancet 1996,
347:569-573.
3. Wotton CW, Sparber A: Surveys of complementary and alter-
native medicine: Part I. General trends and demographic
groups.  J Altern Compl Med 2001, 7:195-208.BMC Public Health 2006, 6:28 http://www.biomedcentral.com/1471-2458/6/28
Page 9 of 9
(page number not for citation purposes)
4. Thomas KJ, Nicholl JP, Coleman P: Use and expenditure on com-
plementary medicine in England: a population based survey.
Comp Ther Med 2001, 9:2-11.
5. Harris P, Rees R: The prevalence of complementary and alter-
native medicine use among the general population: a sys-
tematic review of the literature.  Compl Ther Med 2000, 8:88-96.
6. Marmot M, Feeney A, Shipley M, North F, Syme SL: Sickness
absence as a measure of health status and functioning: from
the UK Whitehall II study.  J Epidemiol Community Health 1995,
49:124-130.
7. Tellnes G, Bjerkedal T: Epidemiology of Sickness Certification.
Scand J Soc Med 1989, 17:245-251.
8. Hemingway H, Shipley M, Stansfeld S, Marmot M: Sickness absence
from back pain, psychosocial work characteristics and
employment grade among office workers.  Scand J Work Environ
Health 1997, 23:121-129.
9. Allebeck P, Mastekaasa A: Risk factors for sick leave – general
studies.  Scand J Public Health 2004, 63:49-108.
10. Bödeker W: Associations between workload and diseases
rarely occurring in sickness absence data.  J Occup Environ Med
2001, 43:1081-1088.
11. Alexanderson K: Sickness absence: a review of performed
studies with focused on levels of exposures and theories uti-
lized.  Scand J Soc Med 1998, 26:241-249.
12. Campbell DT, Kenny DA: A primer on regression artifacts.  The
Guilford Press: New York; 1999. 
13. Bland JM, Altman DG: Statistic notes: regression towards the
mean.  BMJ 1994, 308:1499.
14. Streiner DL: Regression toward the mean: its etiology, diagno-
sis, and treatment.  Can J Psychiatry 2001, 46:72-76.
15. GCP Study Group: The German Cardiovascular Prevention
Study (GCP): Design and methods.  Eur H J 1988, 9:1058-1066.
16. Federal Association of Company Health Insurance Funds: Health
Report 1994.  (in German) BKK Bundesverband: Essen. 
17. Yudkin PL, Stratton IM: How to deal with regression to the
mean in intervention studies.  Lancet 1996, 347:241-243.
18. Chen S, Cox C, Cui L: A more flexible regression-to-the-mean
model with possible stratification.  Biometrics 1998, 54:939-947.
19. Astin JA: Why patients use alternative medicine: Results of a
national study.  JAMA 1998, 279:1548-1553.
20. Bausell RB, Lee WL, Berman BM: Demographic and Health-
Related Correlates of Visits to Complementary and Alterna-
tive Medical Providers.  Med Care 2001, 39:190-196.
21. Druss BG, Rosenheck RA: Association between use of uncon-
ventional therapies and conventional medical services.  JAMA
1999, 282:651-656.
22. Leung JM, Dzankic S, Manku K, Yuan S: The prevalence and pre-
dictors of the use of alternative medicine in presurgical
patients in five California hospitals.  Anesth Analg 2001,
93:1062-1068.
23. Vickers AJ, Rees RW, Zollman CE, Rob McCarney, Smith CM, Ellis N,
Fisher P, Van Haselen R: Acupuncture for chronic headache in
primary care: large, pragmatic, randomised trial.  BMJ 2004,
328:744-747.
24. Feeney A, North F, Head J, Canner R, Marmot M: Socioeconomic
and sex differentials in reason for sickness absence from the
Whitehall II Study.  Occup Environ Med 1998, 55:91-98.
25. Kivimäki M, Vahtera J, Thomson L, Griffiths A, Cox T, Pentti J: Psy-
chosocial factors predicting employee sickness absence dur-
ing economic decline.  J App Psychol 1997, 82:858-872.
26. Kristensens TS: Sickness absence and work strain among Dan-
ish slaughterhosue workers: an analysis of absence from
work regarded as coping behaviour.  Soc Sci Med 1991, 32:15-27.
27. Hörnquist JO, Hansson B, Zar M: Well-being and future sick-
leave. Multivariate analysis with regard to preceding sick-
leave.  Eur J Pub Health 1997, 7:284-290.
28. Melchart D, Linde K, Streng A, Reitmayr S, Hoppe A, Brinkhaus B,
Becker-Witt C, Wagenpfeil S, Pfaffenrath V, Hammes M, Willich SN,
Weidenhammer W: Acupuncture randomised trials (ART) in
patients with migraine or tension-type headache – Design
and protocols.  Forsch Komplementärmed Klass Naturheilkd 2003,
10:179-184.
29. Walach H, Güthlin C: Effects of homeopathy and acupuncture
in general practice – Intermediate results of a longitudinal
observational study as seen in work-absenteeism.  Forsch Kom-
plementärmed Klass Naturheilkd 2002, 7:36.
30. Marstedt G, Moebus S: Gesundheitsberichterstattung des Bun-
des Heft 9 – Inanspruchnahme alternativer Methoden in der
Medizin.  (Federal Health Report No. 9: Health care utilization and prev-
alence of complementary and alternative medicine in Germany) 2002
[http://www.rki.de]. Verlag Robert Koch Institut: Berlin
31. Breaugh JA: Predicting absenteeism from prior absenteeism
and work attitudes.  J Applied Psychology 1981, 66:555-560.
32. North F, Syme SL, Feeney A, Head J, Shipley MJ, Marmot MG:
Explaining socioeconomic differences in sickness absence:
the Whitehall II study.  BMJ 1993, 306:361-366.
33. Rael EGS, Stansfeld SA., Shipley M, Head J, Feeney A, Marmot M:
Sickness absence in the Whitehall II study, London: the role
of social support and material problems.  J Epidemiol Community
Health  1995, 49:474-481.
34. Kristensens TS: Sickness absence and work strain among Dan-
ish slaughterhouse workers: an analysis of absence from
work regarded as coping behaviour.  Soc Sci Med 1991, 32:15-27.
35. Moebus S, Lehmann N, Hoffmann B, Jöckel KH: Prescription pat-
terns of practitioners treating chronically ill patients with
complementary and alternative medicine (CAM) – Results of
a longterm outcome study.  ISTAHC Annu Meet 2002, 18:215.
36. Richardson MA, Post-White J, Singletary SE, Justice B: Recruitment
for complementary/alternative medicine trials: who partici-
pates after breast cancer.  Ann Behav Med 1998, 20:190-198.
37. Ellis PM: Attitudes towards and participation in randomised
clinical trials in oncology: a review of the literature.  Ann Oncol
2000, 11:939-945.
38. Nahin RL, Straus SE: Research into complementary and alter-
native medicine: problems and potential.  BMJ 2001,
322:161-164.
39. White AR, Ernst E: The case for uncontrolled clinical trials: a
starting point for the evidence base for CAM.  Complementar
Ther Med 2001, 9:11-115.
40. Cummings P, Weiss NS: Case series and exposure series: the
role of studies without controls in providing information
about the etiology of injury or disease.  Injury Prevention 1998,
4:54-57.
41. Kunz R, Oxman AD: The unpredictability paradox: Review of
empirical comparisons of randomised and non-randomised
clinical trials.  BMJ 1998, 317:1185-1190.
42. Concato J, Shah N, Horwitz RI: Randomised, controlled trials,
observational studies, and the hierarchy of research designs.
N Engl J Med 2000, 342:1887-1892.
43. Britton A, McKee M, Black N, McPerson K, Sanderson C, Bain C:
Choosing between randomised and non-randomised studies:
A systematic review.  Health Technol Assess 1998, 13:1-136.
44. Benson K, Hartz AJ: A comparison of observational studies and
randomised, controlled trials.  N Engl J Med 2000,
342:1878-1886.
45. Lüdtke R, Weber U, Fischer I, Friese KH, Moeller H: An example
on the value of non-randomisation in clinical trials in comple-
mentary medicine.  Forsch Komplementärmed Klass Naturheilk 2003,
9:105-109.
46. Rosenbaum PR: Choice as an alternative to control in observa-
tional studies.  Stat Sci 1999, 14:259-304.
47. Moses L: Measuring effects without randomised trials?
Options, problems, challenges.  Med Care 1995, 33:AS8-AS14.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2458/6/28/prepub